
Keywords: AML, Acute myeloid leukaemia; DDS, Drug delivery system; DNR, Daunorubicin; DOX, Doxorubicin; Eme, Emetine; FA, Folate; FR2, Folic acid receptor 2 (β); HEPC, Hydrogenated egg phosphatidylcholine; MTX, Methotrexate; PE, Phosphatidylethanolamine; PEG, Polye